Dyadic International (NASDAQ:DYAI) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Dyadic International (NASDAQ:DYAI) released its earnings results on Wednesday. The biotechnology company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01), FiscalAI reports. Dyadic International had a negative return on equity of 695.96% and a negative net margin of 239.67%.The company had revenue of $1.11 million during the quarter, compared to analysts’ expectations of $0.90 million.

Here are the key takeaways from Dyadic International’s conference call:

• Dyadic said it is transitioning from a platform company to a more commercial biotech, with products now launched, shipped, sampled, and beginning to generate revenue through direct sales, OEM distribution, milestone payments, and partnerships.
• Q1 2026 revenue rose 182% year over year to about $1.1 million, driven largely by higher R&D and grants-related activity, while the net loss improved modestly to about $1.95 million.
• The company highlighted multiple commercialization wins, including Proliant’s launch of AlbuFree DX, Enzymes’ commercial launch of recombinant bovine chymosin, and first commercial shipments of DNase I and transferrin through its IBT Bioservices distribution agreement.
• Management said customer interest is increasing across life sciences, food and nutrition, and industrial markets, including initial purchase orders in cultivated meat and expanded sampling in Asia-Pacific and Europe through partners like Intralink and FermBox Bio.
• Dyadic ended the quarter with about $6.6 million in cash, restricted cash, and investment-grade securities, and management reiterated that existing resources should fund operations into Q2 2027 if cash burn stays near recent levels.

Dyadic International Stock Down 1.7%

Shares of Dyadic International stock traded down $0.01 on Wednesday, reaching $0.71. The company’s stock had a trading volume of 124,868 shares, compared to its average volume of 70,427. Dyadic International has a 52 week low of $0.65 and a 52 week high of $1.35. The firm’s fifty day simple moving average is $0.82 and its two-hundred day simple moving average is $0.88. The company has a quick ratio of 2.68, a current ratio of 2.68 and a debt-to-equity ratio of 4.08. The company has a market capitalization of $25.89 million, a price-to-earnings ratio of -2.84 and a beta of 1.18.

Institutional Investors Weigh In On Dyadic International

Institutional investors have recently modified their holdings of the business. Bank of America Corp DE boosted its holdings in Dyadic International by 16,146.7% in the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 26,965 shares during the last quarter. Geode Capital Management LLC raised its stake in Dyadic International by 13.7% during the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after buying an additional 36,266 shares during the last quarter. Finally, Landscape Capital Management L.L.C. bought a new position in shares of Dyadic International during the 3rd quarter valued at $190,000. 27.95% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Dyadic International in a research report on Friday, March 27th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $3.00.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.